ARMO BioSciences
Acquired
Immune system activation for cancer treatment
- Headquarters
- Redwood City, California
- Employees
- 11–50
- Founded
- 2011
- Business Model
- B2B
- Website
- lilly.com
- Total Funding
- $167.0M
- Last Round
- $67.0M Series CAug 2017
About
ARMO BioSciences was a late-stage immuno-oncology biotech company developing a pipeline of novel proprietary product candidates, including pegilodecakin (AM0010), to activate the immune system for treating solid tumors and cancers. The company was acquired by Eli Lilly in 2020 for $1.6 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account